Clinical Trial

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Name: Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias — clinical trial record (NCT07447817)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-25.

Trial Details

NCT Number	NCT07447817
Lead Sponsor	John Mascarenhas Collaborators: Sobi, Inc., Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Conditions	Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Enrollment	26 participants
Start Date	2026-05-04
Primary Completion	2030-05-24 (estimated)
Study Completion	2030-05-24 (estimated)
Updated on ClinicalTrials.gov	2026-03-18